This is the first large-scale multicenter study of an 18F-labeled PET molecular contrast agents for visualizing amyloid plaques – – Previous PET imaging of amyloid plaque have involved the use of 11C-labeled radiopharmaceuticals that have a very short life due to the short half-life of 11C. On the other hand, 18F – AV-45 can be used for several hours after the production of the longer half life of 18F radiopharmaceuticals whereby 18F-AV-45. Convenient for larger scale availability in the future.. This U.S. Phase II trial of 18F-AV-45 approximately 200 patients with varying degrees of memory loss in more than 30 centers around the country to participate, the study includes a single administration of 18F – AV-45.
Avid’s novel diagnostic imaging agents to enable earlier diagnosis and more effective treatment selection and therapeutic monitoring of patients through a series of major medical illnesses. The company is a pioneer in the development of molecular imaging agents for Alzheimer’s disease that could lead to earlier diagnosis and better evaluation of drugs designed to prevent or reverse amyloid plaque buildup in the brain. Of diabetes mellitus. Imaging techniques such as positron emission tomography and single photon computed tomography . Avid is currently accepting in clinical studies in clinical studies of 18F – PET agents for imaging amyloid plaques in Alzheimer’s disease and for imaging the vesicular monoamine transporter in diseases with dopaminergic degeneration such as Parkinson’s disease and dementia Lewy bodies .On 20 400,000 U.S. Dollars , a three-year the project at the municipal level to 100,000 practitioners across China exercise in diabetes the prevention and treatment was initiated. The project also offers a web-based learning platform expect diabetes training over 400,000 subscriptions to deliver annual. Another project is on the 5th Trainings are start Oct. In glucose management for 1,000 community-based healthcare providers.